Proteolysis of Aβ Peptide from Alzheimer Disease Brain by Gelatinase A
Open accessThe DOI matches its Crossref record.
Abstract
It has been recently reported that the 72 kDa proteolytic enzyme gelatinase A/type IV collagenase/matrix metalloproteinase 2 (MMP2) hydrolyzed the Lys 16-Leu 17 peptide bond of a synthetic decapeptide (YEVHHQKLVFF) representing the soluble A beta sequence of amino acid residues 10-20. Our aim was to test if this enzyme could also degrade the insoluble 40-42 residues long A beta peptides purified from Alzheimer Disease brain. Our results indicate that MMP2 hydrolyzes A beta 1-40 and A beta 1-42 peptides at Lys 16-Leu 17, at Leu 34-Met 35, and Met 35-Val 36 peptide bonds. These results suggest that MMP2 has the ability of degrading A beta of AD in vitro. If this hydrolysis also occurs in the brain's extracellular matrix, the enzymatic action of gelatinase a could prevent the generation of amyloidogenic A beta 1-40(42).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Matrix metalloproteinases and diseases of the CNS
Wee Yong, V., Forsyth, P. A., Bell, R., Krekoski, C. A., & Edwards, D. R. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01169-7 · Cited by 639
Zinc Metabolism in the Brain: Relevance to Human Neurodegenerative Disorders
Cuajungco, M. P., & Lees, G. J. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0163 · Cited by 541
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
Cauwe, B., Van den Steen, P. E., & Opdenakker, G. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701340019 · Cited by 381
Synaptically released zinc: Physiological functions and pathological effects
Frederickson, C. J., & Bush, A. I. (2001) · Biometals · doi:10.1023/a:1012934207456 · Cited by 363
Itoh, T., Ikeda, T., Gomi, H., Nakao, S., Suzuki, T., & Itohara, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22389 · Cited by 356
Levi, E., Fridman, R., Miao, H. Q., Ma, Y. S., Yayon, A., & Vlodavsky, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7069 · Cited by 351
Self-citationBackstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A., & Klagsbrun, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31730 · Cited by 330
Shirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008511200 · Cited by 311
White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview
Chandler, S., Miller, K. M., Clements, J. M., Lury, J., Corkill, D., Anthony, D. C. C., Adams, S. E., & Gearing, A. J. H. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00179-8 · Cited by 273
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 261
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9
Hernandez-Guillamon, M., Mawhirt, S., Blais, S., Montaner, J., Neubert, T. A., Rostagno, A., & Ghiso, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610931 · Cited by 137
Pihlaja, R., Koistinaho, J., Kauppinen, R., Sandholm, J., Tanila, H., & Koistinaho, M. (2011) · Glia · doi:10.1002/glia.21212 · Cited by 96
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
Liao, M.-C., & Van Nostrand, W. E. (2010) · Biochemistry · doi:10.1021/bi901994d · Cited by 92
Characterization of the Soluble Form of the Low Density Lipoprotein Receptor-Related Protein (LRP)
Quinn, K. A., Pye, V. J., Dai, Y.-P., Chesterman, C. N., & Owensby, D. A. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4590 · Cited by 90
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
“In this way, MT1-MMP joins the list of metalloproteinases with Aβ-degrading, activity, such as MMP-2, MMP-3, MMP-7 and MMP-9 (Roher et al., 1994; Backstrom et al., 1996; Deb et al., 2003; White et al., 2006; Yan et al., 2006; Yin et al., 2006; Hernandez-Guillamon et al., 2010, 2015; Liao and Van Nostrand, 2010; Py et…”
Backgroundβ-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes
Deb, S., Wenjun Zhang, J., & Gottschall, P. E. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02344-8 · Cited by 81
Py, N. A., Bonnet, A. E., Bernard, A., Marchalant, Y., Charrat, E., Checler, F., Khrestchatisky, M., Baranger, K., & Rivera, S. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00247 · Cited by 76
Nitric oxide‐mediated regulation of ‐amyloid clearance via alterations of MMP‐9/TIMP‐1
Ridnour, L. A., Dhanapal, S., Hoos, M., Wilson, J., Lee, J., Cheng, R. Y. S., Brueggemann, E. E., Hines, H. B., Wilcock, D. M., Vitek, M. P., et al. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12028 · Cited by 54
Pinto, M., Pickrell, A. M., Fukui, H., & Moraes, C. T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.014 · Cited by 47
The microglial lysosomal system in Alzheimer’s disease: Guardian against proteinopathy
Van Acker, Z. P., Perdok, A., Bretou, M., & Annaert, W. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101444 · Cited by 45
Paumier, J.-M., Py, N. A., García-González, L., Bernard, A., Stephan, D., Louis, L., Checler, F., Khrestchatisky, M., Baranger, K., & Rivera, S. (2019) · The FASEB Journal · doi:10.1096/fj.201801076r · Cited by 40
Hernández‐Guillamon, M., Delgado, P., Ortega, L., Pares, M., Rosell, A., García‐Bonilla, L., Fernández‐Cadenas, I., Borrell‐Pagès, M., Boada, M., & Montaner, J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22034 · Cited by 39
Ou-Yang, M.-H., & Van Nostrand, W. E. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-134 · Cited by 30
Metadata
- Authors
- Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J., & Fridman, R.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 1994-12
- Volume
- 205
- Issue
- 3
- Pages
- 1755-1761
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2002755165
- Cited by
- 136
- References
- 0
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.